



Express Mail No. EV913330535US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Pramod K. Srivastava

Confirmation No. 6470

Application No.: 10/532,660

Group Art Unit: To be assigned

Filed: January 27, 2006

Examiner: To be assigned

Attorney Docket No.: 8449-323-999

IMMUNOTHERAPY OF A CANCER THROUGH

CONTROLLED CELL LYSIS

APPARATUS AND METHOD FOR

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

For:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Applicant hereby directs the Examiner's attention to the references A01-A19, B01-B17 and C01-C14 listed on the attached form entitled "List of References Cited by Applicant." Legible copies of references B01-B17 and C01-C14 are being submitted herewith.

Identification of the listed references is not to be construed an admission of Applicant or Attorneys for Applicant that such references are available as "prior art" against the subject application.

Applicant respectfully requests that the Examiner review the listed references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b), since this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent and Trademark Office determine otherwise, please charge the required fee to Jones Day Deposit Account No. 50-3013; a duplicate of this sheet is enclosed.

Respectfully submitted,

Date:

November 16, 2006

gallane

M. Autler 32,605 (Reg. No.)

JONES DAY

222 East 41st Street

New York, New York 10017

(212) 326-3939

Enclosures

EXPRESS MAIL NO.: EV913330535US

1743

Sheet 1 of 3 of List of References

of Application No. 10/532,660

REFERENCES CITED BY APPLICANT (Use several sheets if necessary)

APPLICATION NO. ATTY. DOCKET NO. 8449-323-999 10/532,660 **APPLICANT** Pramod K. Srivastava **ART UNIT** FILING DATE

January 27, 2006

				TENT DOCUMENTS	
*Examiner		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A01	5,750,119	5/12/1998	Srivastava	
	A02	5,837,251	11/17/1998	Srivastava	
	A03	5,935,576	8/10/1999	Srivastava	
	A04	5,961,979	10/5/1999	Srivastava	
	A05	5,997,873	12/7/1999	Srivastava	
	A06	6,007,821	12/28/1999	Srivastava et al.	
	A07	6,017,540	1/25/2000	Srivastava et al.	
	A08	6,030,618	2/29/2000	Srivastava	
	A09	6,048,530	4/11/2000	Srivastava	
	A10	6,168,793	6/2/2001	Srivastava	
	A11	6,194,388	2/27/2001	Krieg et al.	
	A12	6,207,646	3/27/2001	Krieg et al.	
	A13	6,218,371	4/17/2001	Krieg et al.	
	A14	6,239,116	5/29/2001	Krieg et al.	
	A15	6,339,068	1/15/2002	Krieg et al.	
	A16	6,406,705	6/18/2002	Davis et al.	
	A17	6,410,027	6/25/2002	Srivastava	·
	A18	6,429,199	8/6/2002	Krieg et al.	
	A19	6,455,503	9/24/2002	Srivastava	

	FOREIGN PATENT DOCUMENTS						
*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	т	
	B01	EP 700445 B1	3/13/1996	EP			
	B02	WO 00/06588	2/10/2000	PCT			
	B03	WO 01/12223 A2	2/22/2001	PCT			
	B04	WO 01/12804 A2	2/22/2001	PCT			
	B05	WO 01/22972 A2	4/5/2001	PCT			

NYJD-1630347v2

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXPRESS MAIL NO.: EV913330535US Sheet 2 of 3 of List of References

cι	2 01	2 01	DISCOT	Keleicies
of	App	licati	on No.	10/532,660

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.	
8449-323-999	10/532,660	
APPLICANT		
Pramod K. Srivastava		
FILING DATE	ART UNIT	
January 27, 2006	1743	

*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т
	B06	WO 01/35991 A2	5/25/2001	РСТ		
	B07	WO 01/55370 A2	8/2/2001	PCT		
	B08	WO 01/83503 A2	11/8/2001	PCT		
	B09	WO 01/91787	12/6/2001	PCT		
	B10	WO 01/92474	12/6/2001	PCT		
	B11	WO 02/052002 A2	7/4/2002	PCT		
	B12	WO 02/26757 A2	4/4/2002	PCT		
	B13	WO 02/30434	4/18/2002	PCT		
	B14	WO 97/06821	2/27/1997	PCT		
	B15	WO 98/55495 A2	12/10/1998	PCT		
	B16	WO 99/22761	5/14/1999	PCT		
4	B17	WO 99/62923 A2	12/9/1999	PCT		\vdash

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
IIIIII	C01	BASU et al., "CD91 Is a Common Receptor for Heat Shock Proteins gp96, hsp90, hsp70, and Calreticulin," Immunity, 14:303-313 (2001).	
	C02	BASU et al., "Necrotic But Not Apoptotic Cell Death Releases Heat Shock Proteins, Which Deliver A Partial Maturation Signal to Dendritic Cells and Activate the NF-kappa B Pathway," Int. Immunol, 12:1539-46 (2000).	
-	C03	BINDER et al., "CD91: A Receptor for Heat Shock Protein gp96," Nat. Immunol., 1:151-5 (2000).	
	C04	BINDER et al., "Heat Shock Protein gp96 Induces Maturation and Migration of CD11c [†] Cells in Vivo," J. Immunol. 165:6029-6034 (2000).	
	C05	CASSEL et al., "Viral Oncolysate in the Management of Malignant Melanoma," Cancer, 40:672-79 (1977).	
	C06	GALLUCCI et al., "Natural Adjuvants: Endogenous Activators and Dendritic Cell," Nat Med 5:1249-55, (1999).	
	C07	HOOS et al., "Vaccination with heat shock protein-peptide complexes: from basic science to clinical applications", Expert Rev. Vaccines 2(3):369-79 (2003).	
	C08	HUGHES et al., "A Study in Clinical Cancer Immunotherapy," Cancer, 26(2):269-78 (1970).	
	C09	HUMPHREY et al., "Adjuvant Immunotherapy for Melanoma," Journal of Surgical Oncology, 25:303-05 (1984).	
	C10	MANJILI et al., "Immunotherapy of cancer using heat shock proteins", Frontiers Bioscience,7:d43-52 (2002).	
	CII	OETTGEN et al., "The History of Cancer Immunotherapy, in Introduction to the Biologic Therapy of Cancer," De Vitta, V.T. Hellman, S and Rosenberg, S.A. Editors, Lippincott, Philadelphia, pp. 87-119 (1991).	

NYJD-1630347v2

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXPRESS MAIL NO.: EV913330535US

Sheet 3 of 3 of List of References

of Application No. 10/532,660			_	-	_				
	C	ρf	A	pp	li	cation	No.	10/532,660	

LIST	OF	REFERENCES	CITED B	Y APPLIC	CANT
------	-----------	------------	---------	----------	------

(Use several sheets if necessary)

ATTY. DOCKET NO.	APPLICATION NO.
8449-323-999	10/532,660
APPLICANT	
Pramod K. Srivastava	
FILING DATE	ART UNIT
 January 27, 2006	1743

		NON PATENT LITERATURE DOCUMENTS	
*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C12	PANJWANI et al., "Heat Shock Proteins gp96 and hsp70 Activate the Release of Nitric Oxide by APC's," J. Immunol. 168:2997-3003 (2002).	
	C13	SAUTER et al., "Consequences of Cell Death: Exposure to Necrotic Tumor Cells, But Not Primary Tissue Cells or Apoptic Cells, Induces the Maturation of Immunostimulatory Dendritic Cells," J Exp Med, 191:423-34 (2000).	
<u> </u>	C14	SOMERSAN et al., "Primary Tumor Tissue Lysates Are Enriched in Heat Shock Proteins and Induce the Maturation of Human Dendritic Cells," J. Immunol, 167:4844-52 (2001).	

NYJD-1630347v2

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.